These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

510 related items for PubMed ID: 19071172

  • 1. Passive transfer of Plasmodium falciparum MSP-2 pseudopeptide-induced antibodies efficiently controlled parasitemia in Plasmodium berghei-infected mice.
    Martínez PA, Yandar N, Lesmes LP, Forero M, Pérez-Leal O, Patarroyo ME, Lozano JM.
    Peptides; 2009 Feb; 30(2):330-42. PubMed ID: 19071172
    [Abstract] [Full Text] [Related]

  • 2. Protection against malaria is conferred by passive transferring rabbit F(ab)(2)' antibody fragments, induced by Plasmodium falciparum MSP-1 site-directed designed pseudopeptide-BSA conjugates assessed in a rodent model.
    Lozano JM, Lesmes LP, Gallego GM, Patarroyo ME.
    Mol Immunol; 2011 Jan; 48(4):657-69. PubMed ID: 21131051
    [Abstract] [Full Text] [Related]

  • 3. Protective immunization with invariant peptides of the Plasmodium falciparum antigen MSA2.
    Saul A, Lord R, Jones GL, Spencer L.
    J Immunol; 1992 Jan 01; 148(1):208-11. PubMed ID: 1727867
    [Abstract] [Full Text] [Related]

  • 4. Plasmodium: immunization with carboxyl-terminal regions of MSP-1 protects against homologous but not heterologous blood-stage parasite challenge.
    Rotman HL, Daly TM, Long CA.
    Exp Parasitol; 1999 Jan 01; 91(1):78-85. PubMed ID: 9920045
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Monoclonal antibodies against recombinant histidine-rich protein 2 of Plasmodium falciparum and their use in malaria diagnosis.
    Merwyn S, Gopalan N, Singh AK, Rai GP, Agarwal GS.
    Hybridoma (Larchmt); 2011 Dec 01; 30(6):519-24. PubMed ID: 22149276
    [Abstract] [Full Text] [Related]

  • 7. Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design.
    Singh S, Soe S, Mejia JP, Roussilhon C, Theisen M, Corradin G, Druilhe P.
    J Infect Dis; 2004 Sep 01; 190(5):1010-8. PubMed ID: 15295710
    [Abstract] [Full Text] [Related]

  • 8. Variant-specific antibodies to merozoite surface protein 2 and clinical expression of Plasmodium falciparum malaria in rural Amazonians.
    Scopel KK, da Silva-Nunes M, Malafronte RS, Braga EM, Ferreira MU.
    Am J Trop Med Hyg; 2007 Jun 01; 76(6):1084-91. PubMed ID: 17556615
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge.
    Wang L, Goschnick MW, Coppel RL.
    Infect Immun; 2004 Oct 01; 72(10):6172-5. PubMed ID: 15385527
    [Abstract] [Full Text] [Related]

  • 11. Regulation of antibody specificity to Plasmodium falciparum merozoite surface protein-1 by adjuvant and MHC haplotype.
    Chang SP, Nikaido CM, Hashimoto AC, Hashiro CQ, Yokota BT, Hui GS.
    J Immunol; 1994 Apr 01; 152(7):3483-90. PubMed ID: 8144929
    [Abstract] [Full Text] [Related]

  • 12. Passive immunization with antibodies against three distinct epitopes on Plasmodium yoelii merozoite surface protein 1 suppresses parasitemia.
    Spencer Valero LM, Ogun SA, Fleck SL, Ling IT, Scott-Finnigan TJ, Blackman MJ, Holder AA.
    Infect Immun; 1998 Aug 01; 66(8):3925-30. PubMed ID: 9673281
    [Abstract] [Full Text] [Related]

  • 13. A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies.
    Theisen M, Soe S, Brunstedt K, Follmann F, Bredmose L, Israelsen H, Madsen SM, Druilhe P.
    Vaccine; 2004 Mar 12; 22(9-10):1188-98. PubMed ID: 15003647
    [Abstract] [Full Text] [Related]

  • 14. Plasmodium chabaudi: immunogenicity of a highly antigenic glutamate-rich protein.
    Wiser MF, Giraldo LE, Schmitt-Wrede HP, Wunderlich F.
    Exp Parasitol; 1997 Jan 12; 85(1):43-54. PubMed ID: 9024201
    [Abstract] [Full Text] [Related]

  • 15. Novel monoclonal antibody against truncated C terminal region of Histidine Rich Protein2 (PfHRP2) and its utility for the specific diagnosis of malaria caused by Plasmodium falciparum.
    Verma R, Jayaprakash NS, Vijayalakshmi MA, Venkataraman K.
    Exp Parasitol; 2015 Mar 12; 150():56-66. PubMed ID: 25592728
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antibodies to a Plasmodium falciparum blood-stage antigen as a tool for predicting the protection levels of two malaria-exposed populations.
    Astagneau P, Roberts JM, Steketee RW, Wirima JJ, Lepers JP, Deloron P.
    Am J Trop Med Hyg; 1995 Jul 12; 53(1):23-8. PubMed ID: 7542843
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Mapping the anatomy of a Plasmodium falciparum MSP-1 epitope using pseudopeptide-induced mono- and polyclonal antibodies and CD and NMR conformation analysis.
    Lozano JM, Espejo F, Ocampo M, Salazar LM, Tovar D, Barrera N, Guzmán F, Patarroyo ME.
    J Struct Biol; 2004 Oct 12; 148(1):110-22. PubMed ID: 15363791
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants.
    Sachdeva S, Mohmmed A, Dasaradhi PV, Crabb BS, Katyal A, Malhotra P, Chauhan VS.
    Vaccine; 2006 Mar 15; 24(12):2007-16. PubMed ID: 16377036
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.